Monte Rosa Therapeutics, Inc. Common Stock GLUE
$15.50
-2.15%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $29.20
- Implied Upside
- +88.4%
- Price Target Range
- $27.00 – $37.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-07 | JP MorganBrian Cheng |
Maintains | Overweight | $31 → $27 |
| 2026-08-07 | GuggenheimMichael Schmidt |
Maintains | Buy | $35 → $28 |
| 2026-08-07 | Wells FargoDerek Archila |
Maintains | Overweight | $29 → $27 |
| 2026-08-03 | WedbushRobert Driscoll |
Maintains | Outperform | $37 → $27 |
| 2026-06-30 | GuggenheimMichael Schmidt |
Maintains | Buy | $30 → $35 |
| 2026-05-11 | JP MorganBrian Cheng |
Maintains | Overweight | $30 → $31 |
| 2026-03-18 | GuggenheimMichael Schmidt |
Maintains | Buy | $34 → $30 |
| 2026-03-18 | Wells FargoDerek Archila |
Maintains | Overweight | $30 → $29 |
| 2026-01-14 | Piper SandlerEdward Tenthoff |
Reiterates | Overweight | $28 → $37 |
| 2026-01-08 | Wells FargoDerek Archila |
Maintains | Overweight | $22 → $30 |
| 2026-01-08 | GuggenheimMichael Schmidt |
Maintains | Buy | $16 → $34 |
| 2025-12-16 | Wells FargoDerek Archila |
Upgrades | Equal-weight → Overweight | $13 → $22 |
| 2025-11-07 | Wells FargoDerek Archila |
Maintains | Equal-weight | $10 → $13 |
| 2025-03-21 | Wells FargoDerek Archila |
Maintains | Equal-weight | $11 → $10 |
| 2025-03-21 | WedbushRobert Driscoll |
Maintains | Outperform | $15 → $17 |
| 2025-03-12 | LifeSci Capital |
Initiates coverage on | Outperform | $19 |
| 2024-12-19 | Wells FargoDerek Archila |
Downgrades | Overweight → Equal-weight | $14 → $11 |
| 2024-09-12 | WedbushRobert Driscoll |
Reiterates | Outperform | $11 |
| 2024-08-12 | Wells FargoDerek Archila |
Maintains | Overweight | $18 → $17 |
| 2024-06-28 | Piper SandlerEdward Tenthoff |
Reiterates | Overweight | $16 |
| 2024-05-22 | WedbushRobert Driscoll |
Reiterates | Outperform | $11 |
| 2024-02-15 | WedbushRobert Driscoll |
Initiates coverage on | Outperform | $11 |
| 2023-10-19 | JP MorganEric Joseph |
Maintains | Overweight | $31 → $11 |
| 2023-08-11 | Credit SuisseRichard Law |
Reiterates | Neutral | $11 |
| 2023-05-12 | Credit SuisseRichard Law |
Reiterates | Neutral | $11 |
| 2023-03-17 | Credit SuisseRichard Law |
Maintains | Neutral | $12 → $11 |
| 2023-01-03 | Wells FargoDerek Archila |
Upgrades | Equal-weight → Overweight | $19 |
| 2022-10-13 | UBSEliana Merle |
Initiates coverage on | Buy | $22 |
| 2022-08-15 | JefferiesKelly Shi |
Initiates coverage on | Buy | $20 |
| 2022-05-12 | Piper SandlerEdward Tenthoff |
Maintains | Overweight | $40 → $21 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $15.50
- Market Cap
- $1.36 billion
- 52-Week Range
- $4.12 – $25.77
- Average Volume
- 1.41 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.